OFI Invest Asset Management Buys 3,317 Shares of Boston Scientific Corporation $BSX

OFI Invest Asset Management boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 34.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,817 shares of the medical equipment provider’s stock after purchasing an additional 3,317 shares during the quarter. OFI Invest Asset Management’s holdings in Boston Scientific were worth $1,377,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in BSX. 1248 Management LLC purchased a new position in shares of Boston Scientific during the 1st quarter valued at $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the 1st quarter valued at $27,000. Sound Income Strategies LLC grew its position in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Boston Scientific during the 2nd quarter valued at $37,000. Finally, Activest Wealth Management grew its position in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Barclays boosted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Truist Financial boosted their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $120.71.

Boston Scientific Stock Performance

Boston Scientific stock opened at $95.41 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $141.38 billion, a PE ratio of 56.79, a P/E/G ratio of 2.30 and a beta of 0.61. The firm has a fifty day simple moving average of $101.98 and a two-hundred day simple moving average of $101.86. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.